US/UK/Canada

Share

Contacts

  • Pia Renaudin

    • Links

    Pick a time period -
    Tags ( Active)

    SciBase Submits FDA 510(k) to Expand Nevisense into the Largest Skin Cancer Market

    STOCKHOLM, Sweden – July 1, 2026 – SciBase Holding AB ("SciBase") [STO: SCIB) a leader in AI-based devices for detection and prevention in dermatology, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the U.S. indication for Nevisense to include the assessment of Non-Melanoma Skin Cancers (keratinocyte skin cancers).Nevisense is currently the only FDA-approved AI-driven technology in dermatology for the assessment and early detection of melanoma. If cleared, the expanded indication would extend the clinical

    First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase

    STOCKHOLM, Sweden – June 10, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction in Atopic Dermatitis.The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD). This milestone marks a significant step forward in understanding and managing this chronic, inflammatory skin condition, which affects millions of people worldwide. The study, titled DETECT-AD, the first

    Study that highlights Nevisense potential for prediction of AD published in leading journal

    STOCKHOLM, Sweden – June 9, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-powered skin health solutions, today announced the publication of a study in the peer-reviewed journal Allergy  demonstrating that results from Nevisense measurements obtained shortly after birth identified children who subsequentially developed atopic dermatitis (AD).The study, which was previously orally presented at the AAAAI conference in Philadelphia February 27 – March 2, was conducted by researchers at the Icahn School of Medicine at Mount Sinai and assessed neonatal skin barrier

    SciBase announces that the board of directors has resolved on the record date for the reverse share split

    SWEDEN – May 28, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, today announces that the board of directors has resolved on the record date for the reverse share split. At the Annual General Meeting of SciBase Holding AB (publ) ("SciBase" or the "Company") on 19 May 2026, it was resolved on a reverse share split of the Company's shares, whereby one hundred (100) existing shares shall be consolidated into one (1) share (Sw. sammanläggning 1:100) (the "Reverse Share Split"). The board of directors was further

    Nevisense detects skin barrier damage by chemicals used in household cleaning products in a new ex-vivo study

    SWEDEN – May 28, 2026 - SciBase Holding AB ("SciBase") [STO: SCIB], a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to show that surfactants in household cleaning products disrupt the human skin barrier.In the study, human ex vivo skin samples were exposed to Sodium dodecyl sulfate (SDS), a surfactant in household cleaning products which

    Bulletin from the annual general meeting in SciBase Holding AB (publ)

    Today, the annual general meeting 2026 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to convene the meeting (which is available on the Company's website (www.scibase.com)).The annual general meeting resolved: · to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025;  · that no dividend shall be paid for the financial year 2025 and that the year's result shall be carried

    SciBase Announces New Research Highlighting Nevisense’s Potential in Detecting Age-Related Skin Barrier Changes

    STOCKHOLM, Sweden – May 18, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced the presentation of a new study at the Society for Investigative Dermatology (SID) Annual Meeting. The study, conducted by prof. Abuabara and Dr. Zhu at UCSF (The University of California, San Francisco), demonstrates that SciBase’s proprietary Electrical Impedance Spectroscopy (EIS) technology, featured in the Nevisense platform, can successfully detect and quantify age-related changes in the skin barrier.While Nevisense is

    Interim report

    January 1 – March 31, 2026The first quarter in figures · Net sales were TSEK 14,278 (8,856), +61%, cleared for currency effects +80%. · The loss after tax was TSEK 24,490 (20,682). · The loss per share was SEK 0.03 (0.07). · The cash flow from current operations was negative in the amount of TSEK 26,573 (26,001). · The gross margin was 49.2% (70.5%). · Electrode sales volume increased by 70% and was 30,460 (17,870) units. Repeat sales of electrodes to existing customers increased by 73% (incl deliveries to Castle). Important events during the quarter · Overall

    SciBase publishes the Annual report for 2025

    SciBase hereby announces that the Annual report for 2025 is available at the Company’s website www.scibase.com.A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFOTel: +46 70 341 34 72 E-mail: michael.colerus@scibase.com Certified Advisor: DNB Carnegie Investment Bank AB (publ)Tel: +46 8 588 68 570Email: certifiedadviser@carnegie.se The information was submitted for

    Notice to attend the annual general meeting in Scibase Holding AB (publ)

    Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 19 May 2026 at 10:00 CEST at BAHR Advokatbyrå, Birger Jarlsgatan 16, in Stockholm. The registration to the meeting will open at 09:30 CEST.This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail. Right to participate and notice of participation A shareholder who wishes to participate at the general meeting must: (i) be recorded in the share register

    SciBase reaches milestone with over 400,000 tests sold with Nevisense

    STOCKHOLM, Sweden – April 7, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced a significant milestone with over 400,000 Nevisense tests sold worldwide.Nevisense is the only FDA-approved and CE-marked non-invasive diagnostic technology used by dermatologists to evaluate suspicious moles and assess a patient’s individual risk of melanoma. By providing more accurate and personalized insights at the point of care, it supports better clinical decision-making. Although Nevisense is currently primarily

    Interim report

    January 1 – December 31, 2025The fourth quarter in figures · Net sales were TSEK 12,475 (8,598), +45%, cleared for currency effects +57%. · The loss after tax was TSEK 25,300 (21,677). · The loss per share was SEK 0.06 (0.10). · The cash flow from current operations was negative in the amount of TSEK 20,824 (12,548). · The gross margin was 63.0% (68.5%). · Electrode sales volume increased by 67% and was 28,634 (17,132) units. Repeat sales of electrodes to existing customers increased by 48%. The full year in figures · Net sales were TSEK 40,461 (29,705), +36%,

    New Study Positions Nevisense’s EIS as a valuable and sensitive tool for assessing skin barrier impairment

    STOCKHOLM, Sweden – March 10, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, is pleased to announce the publication of a pivotal study in the leading journal Contact Dermatitis. The study, titled "Assessing Skin Barrier Integrity: A Comparative Study Using Transepidermal Water Loss, Electrical Impedance Spectroscopy and Corneometry," confirms that Nevisense Electrical Impedance Spectroscopy (EIS) is a robust and effective method for studying skin barrier integrity. The research compared Nevisense EIS technology

    New Publication: US clinicians’ real-world Nevisense experience improves melanoma detection

    STOCKHOLM, Sweden – March 5, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, , announced that Stephen D. Hess, MD, PhD, FAAD, has published a clinical article highlighting his real-world experience integrating Nevisense into routine melanoma detection. The article was published in The Dermatologist, a leading U.S. clinical dermatology journal.In the publication, Dr. Hess outlines how Nevisense provides objective data to complement visual examination and dermoscopy when evaluating atypical pigmented lesions, and that

    SciBase receives approval by FDA for extended labelling in the US

    STOCKHOLM, Sweden – March 2, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure. Previously, the labelling only specified dermatologists as users but now it also includes healthcare professionals such as physician assistants and medical assistants working at dermatology clinics. A dermatologist still needs to initiate the

    SciBase’s Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma

    STOCKHOLM, Sweden – February 19, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense (EIS) is included in the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for melanoma. The guidelines refer to EIS as a diagnostic support technology to aid in the detection of melanoma.NCCN develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]), which are recognized as the standard for clinical policy and patient care in oncology.  “The

    A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns

    STOCKHOLM, Sweden – February 17, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces that results from a new study will be presented in an oral presentation at the AAAAI conference in Philadelphia February 27 – March 2.The study from Icahn school of Medicine of Mount Sinai in New York was conducted on newborns who have a first-degree relative affected by atopic disease - meaning they had an increased risk of developing atopic dermatitis. The study included 19 infants, among whom Nevisense successfully

    Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue

    In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of shares that the board of directors resolved upon on 29 December 2025 (the “Rights Issue”). Following the completed recalculation, SciBase can

    SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2

    SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the final outcome of the rights issue of shares resolved by the Company on 29 December 2025 (the "Rights Issue"). The Rights Issue has been subscribed to 96.4 percent, of which approximately 61.3 percent has been subscribed for with the support of subscription rights and approximately 35.1 percent without the support of subscription rights. Through the Rights Issue, the Company will receive approximately 79.9 MSEK before deduction of transaction costs. Furthermore, the Board of Directors of the Company has today, pursuant

    Change of date for publication of the year-end report for the financial year 2025

    The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has resolved to postpone the publication of the year-end report for the financial year 2025 to March 13, 2026. The reason for the postponement is to align the trading restriction period with the ongoing rights issue, the subscription period of which ends today, January 26, 2026.For more information, please contact: Jesper Høiland, Chairman of the Board, phone +45 612 207 30 Michael Colérus, Chief Financial Officer, phone +46 70 341 34 72 Certified Adviser (CA): DNB Carnegie Investment Bank AB (publ)

    Increased commitment in SciBase rights issue

    STOCKHOLM, Sweden – January 22, 2026 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, announces it has been informed that Life Science Investment Fund 1, one of SciBase larger shareholders have subscribed for their pro rata share of 5.0 percent in the ongoing rights issue. Furthermore, members of SciBase management and board have subscribed for shares in the rights issue totalling 0.6 MSEK in addition to their pro-rata commitments.SciBase is implementing a rights issue of approximately 83 MSEK (the “Rights Issue”), where

    SciBase publishes information document regarding rights issue

    The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue of shares of approximately SEK 83 million (the "Rights Issue") resolved by the Board of Directors of the Company on 29 December 2025.  The information document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website and will also be available on Bergs Securities AB's ("Bergs Securities") website https://www.bergssecurities.se/.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR

    SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2

    SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the repurchase offer for all warrants of series TO 2 resolved by the Board of Directors on 7 November 2025 (the "TO 2 Offer"). The outcome shows that holders of a total of 418,150,952 warrants of series TO 2 have accepted the TO 2 Offer where two (2) warrants of series TO 2 entitle to one (1) newly issued share in the Company. The outcome of the TO 2 Offer corresponds to approximately 83.9 percent of all outstanding warrants of series TO 2 and results in the issuance of 209,075,476 new shares in SciBase.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Youtube